<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00248183</url>
  </required_header>
  <id_info>
    <org_study_id>PRX-CP-007</org_study_id>
    <nct_id>NCT00248183</nct_id>
  </id_info>
  <brief_title>A Study To Evaluate PRX-00023 In Patients With Generalized Anxiety Disorder (GAD)</brief_title>
  <official_title>A Randomized, Double Blind, Placebo Controlled, Multicenter Study To Evaluate The Efficacy, Safety, And Tolerability Of PRX-00023 In Patients With Generalized Anxiety Disorder (GAD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Epix Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Epix Pharmaceuticals, Inc.</source>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo controlled, multi-center outpatient study, in
      adults with GAD.

      Patients 18-65 years of age, with the diagnosis of GAD according to DSM-IV criteria, who
      fulfill the inclusion/exclusion criteria, will be enrolled in this study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo controlled, multi-center outpatient study, in
      adults with GAD.

      Patients 18-65 years of age, with the diagnosis of GAD according to DSM-IV criteria, who
      fulfill the inclusion/exclusion criteria, will be enrolled in this study.

      This is a randomized, double-blind, placebo controlled, multi-center outpatient study, in
      adults with GAD.

      Patients 18-65 years of age, with the diagnosis of GAD according to DSM-IV criteria, who
      fulfill the inclusion/exclusion criteria, will be enrolled in this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">June 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>310</enrollment>
  <condition>Anxiety Disorders</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRX-00023</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be male or female, 18-65 years of age

          -  Meet DSM-IV diagnostic criteria for Generalized Anxiety Disorder (GAD)

          -  Have a total score of ≥ 20 on the HAM-A and a score of ≥ 2 on Items 1 and 2 (anxious
             mood and tension) of the HAM-A

          -  Have no more than a 20% decrease in total HAM-A score during the period from the
             screening visit to the randomization visit

          -  Have a negative serum (β-HCG) pregnancy test at screening and a negative urine
             pregnancy test at baseline (for all women)

          -  Female subjects must meet one of the following criteria: (a) Be surgically sterile
             (i.e., have had bilateral tubal ligation, hysterectomy, or bilateral oophorectomy at
             least six months prior to first dose of PRX-00023; appropriate documentation will be
             required) OR (b) Agree that, if sexually active, they and all male partners will use
             two (2) acceptable barrier forms of contraception (e.g., condoms and diaphragm) from
             screening until one month after the final dose of study drug

          -  Male subjects must agree that they and any female partners will use two(2) acceptable
             forms of contraception (e.g., condoms and hormonal contraceptives) from screening
             until one month following the final dose of study drug

          -  Be in generally good physical health as determined by the Investigator on the basis of
             medical history, physical examination, and screening laboratory results

          -  Have the ability to communicate with the investigative site staff in a manner
             sufficient to carry out all protocol procedures as described

          -  Be able to understand procedures and provide written informed consent prior to
             admission

        Exclusion Criteria:

          -  A history of an inability to tolerate, or a failure to respond to, two or more
             anxiolytic or anti-depressant drugs given in adequate doses and duration for the
             treatment of symptoms present in the current illness

          -  Prior intolerance to buspirone, gepirone, tandospirone or other 5HT1A agonist

          -  A current or past history of mania, bipolar disorder, schizophrenia, or other
             psychotic disorder

          -  A current history (or within the six months prior to screening) of panic disorder,
             post traumatic stress disorder, major depression, obsessive-compulsive disorder,
             social phobia, acute stress disorder, adjustment disorder with anxious mood,
             performance anxiety, somatization disorder, or other principle psychiatric diagnosis
             (DSM-IV) which could interfere with the efficacy assessments

          -  A history of a major life event (e.g. divorce, death of family member) which in the
             opinion of the Investigator is likely to alter the efficacy ratings during the course
             of the study

          -  Clinically significant abnormalities on laboratory tests or ECG (includes QTc value
             &gt;450 msec in males or &gt; 470 msec in females)

          -  The presence of a serious or clinically unstable neurologic, cardiovascular, hepatic,
             renal, endocrinologic, pulmonary, hematologic or other medical illness or psychiatric
             condition that would, in the opinion of the Investigator, compromise participation in
             the study, confound study results, or likely lead to the need for early termination of
             study participation or hospitalization during the course of the study

          -  A history of allergic reactions to two or more medications of different chemical
             classes

          -  Use of any non-prescription drug with psychotropic effects within seven (7) days prior
             to initiation of the placebo lead in

          -  Chronic use of analgesics with opiates (e.g., codeine, hydrocodone, oxycodone) for &gt;6
             months or use of opiates within two weeks prior to screening

          -  Introduction or change in cognitive behavioral therapy, interpersonal therapy, or
             other psychotherapy within three months of screening

          -  Use of St. John's Wort, kava kava, ephedra, or other psychoactive herbal medications
             within the last two weeks before screening

          -  Known or suspected substance abuse or dependence, including alcohol, within one year
             of screening

          -  A positive urine drug screen (e.g., amphetamines, barbiturates, benzodiazepines,
             cannabinoids, cocaine, methadone, methaqualone, opiates, and propoxyphene) at
             screening. The urine drug screen may be repeated once if after discussion with the
             patient there is a plausible reason for the positive test other than substance abuse

          -  A history of suicide attempts in the last two years, or current suicide risk in the
             judgment of the Investigator

          -  Women who are breast feeding, have been lactating within three months prior to
             screening, pregnant, expect to become pregnant during the course of the study, or are
             sexually active and are not using a medically acceptable double barrier method of
             birth control. Women relying solely on oral contraceptives for - The use of any
             investigational drug within 30 days prior to enrollment

          -  The concomitant use of any other antidepressants, anxiolytics, or any other
             psychoactive drugs

          -  Treatment with any potent inhibitor of CYP3A4, including ketoconazole, itraconazole,
             HIV protease inhibitors, clarithromycin, erythromycin, cyclosporine

          -  Treatment with CYP3A4 inducers such as carbamazepine, barbiturates, phenytoin,
             rifampin, or oral glucocorticoids

          -  Treatment with any of the psychoactive drugs listed in the table below within the
             interval specified below before enrollment

          -  Psychoactive drug - Interval (weeks)

               -  MAO Inhibitors - 4

               -  Fluoxetine - 4

               -  Fluvoxamine - 2

               -  Citalopram - 2

               -  Paroxetine - 2

               -  Sertraline - 2

               -  Buspirone - 4

               -  Buproprion - 2

               -  Mirtazepine - 2

               -  Nefazodone - 2

               -  Venlafaxine - 2

               -  Duloxetine - 2

               -  Trazodone - 2

               -  Benzodiazepines Occasional or PRN use: - 1

               -  Chronic or daily use: - 4

               -  Tricyclic and Heterocyclic Antidepressants - 2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vista Medical Research</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pivotal Research Center</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anaheim Research Center</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Clinical Research Group</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91739</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connecticut Clinical Research</name>
      <address>
        <city>Cromwell</city>
        <state>Connecticut</state>
        <zip>06416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The George Washington University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gulf Coast Clinical Research Center</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Institute of Research and Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Behavioral Research</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana Research Associates</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pivotal Research Center</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Neurosciences</name>
      <address>
        <city>Kenilworth</city>
        <state>New Jersey</state>
        <zip>07033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Center for Clinical Investigations</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Center for Clinical Investigations</name>
      <address>
        <city>Salem</city>
        <state>Oregon</state>
        <zip>97301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unversity of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Future Search Trials</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Neurosciences</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Lerfald, MD</name>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <zip>25301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2005</study_first_submitted>
  <study_first_submitted_qc>November 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2005</study_first_posted>
  <last_update_submitted>April 2, 2008</last_update_submitted>
  <last_update_submitted_qc>April 2, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 3, 2008</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naluzotan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

